Duo-5®

Cefpodoxime+ Clavulanic acid

Presentation

Duo-5® LS: Each film coated tablet contains Cefpodoxime 100 mg as Cefpodoxime proxetil USP and Clavulanic acid 62.5 mg as diluted potassium Clavulanate BP.

Duo-5®: Each film coated tablet contains Cefpodoxime 200 mg as Cefpodoxime proxetil USP and Clavulanic acid 125 mg as diluted potassium Clavulanate BP.

Description

Cefpodoxime-Clavulanic acid is a combination of two drugs and is effective against multiple infection types. Clavulanic acid component protects degeneration of cefpodoxime in presence of beta-lactamase enzymes and increases the antibiotic spectrum.

Clavulanic acid in cefpodoxime-Clavulanic preparation prevents the resistance to Cefpodoxime that may increase with continuous usage of the drug. It has shown effectiveness against multiple Gram-positive and Gram-negative bacteria and is generally well tolerated.

Indications and uses

- URTIs
  - -Pharyngitis
  - -Tonsillitis
- LRTIs
  - -Acute exacerbations of chronic bronchitis
  - -Acute community acquired pneumonia
- SSTIs
- UTIs
  - -Cystitis
  - -Uncomplicated urinary tract infections
- Enteric fever
- General gonorrhea and rectal gonococcal infections

Type of Infections	Dosage Frequency	Duration
Pharyngitis and/or tonsillitis	100 mg 12 hrly	5 to 10 days
Acute community acquired pneumonia	200 mg 12 hrly	14 days
Acute bacterial exacerbations of chronic bronchitis	200 mg 12 hrly	10 days
Uncomplicated gonorrhea and rectal gonococcal infections	Single dose	
Skin and skin structure	400 mg 12 hrly	7 to 14 days
Uncomplicated urinary tract infection	100 mg 12 hrly	7 days
Acute maxillary sinusitis	200 mg 12 hrly	10 days
Enteric fever	200 mg 12 hrly	7-14 days

Patients with renal dysfunction

For patients with severe renal impairment (< 30 ml/min creatinine clearance), the dosing intervals should be increased to 24 hrly. In patients maintained on hemodialysis, the dose frequency should be 3 times/week after hemodialysis.

Patients with cirrhosis

Cefpodoxime pharmacokinetics in cirrhotic patients (with or without ascites) is similar to those in healthy subjects. Dose adjustment is not necessary in this population.

Side effects

It has very few side effects. The side effects include diarrhoea, nausea, skin and vaginal fungal infection, vulvo-vaginal infections, abdominal pain and headache.

Precaution

Cross hypersensitivity in penicillin sensitive patients, leading to serious acute hypersensitivity reactions may need treatment with epinephrine along with other emergency measures such as intravenous fluids, oxygen, airway management and intravenous antihistamine, as clinically indicated.

Contraindication

It is contraindicated in patients with a known allergy to cefpodoxime and clavulanic acid or to the cephalosporin group of antibiotics.

Use in pregnancy and lactation

Pregnancy

Cefpodoxime is pregnancy category B. Although Clavulanic acid has not been shown to have any mutagenic potential, insufficient experimental data are available to allow its recommendation for use in pregnancy.

Nursing mothers

Cefpodoxime is excreted in human milk. So a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mothers.

Drug interactions

Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduce peak plasma level by 24% to 42% and the extent of absorption by 27% to 32% respectively.

Probenecid: Renal excretion of Cefpodoxime proxetil was inhibited by Probenecid and resulted in an approximately 31% increase in AUC.

Nephrotoxic drugs: Close monitoring of renal function is advised when Cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.

Commercial pack

Duo-5® LS: Each Box containing 2 Alu-Alu blister strips of 6 tablets.

Duo-5®: Each Box containing 3 Alu-Alu blister strips of 4 tablets.

Manufactured by
Incepta Pharmaceuticals Ltd
Dhaka, Bangladesh
® Registered Trademark

V.N. 01
DU1